Split History
ETFs Holding EIGR »    EIGR Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Eiger BioPharmaceuticals is a commercial-stage biopharmaceutical company. Co.'s portfolio includes a late-stage clinical development pipeline with five clinical product candidates and one U.S. Food and Drug Administration (FDA)-approved product. Co.'s clinical product candidates include: Lonafarnib for Hepatitis Delta Virus (HDV), Peginterferon Lambda for HDV, Combination Therapy for HDV; Peginterferon Lambda (lambda) for COVID-19, Avexitide in Congenital Hyperinsulinism, and Avexitide in Post-Bariatric Hypoglycemia. Co. has received FDA approval for Zokinvy to reduce the risk of mortality in Progeria and to treat processing-deficient Progeroid Laminopathies. According to our EIGR split history records, Eiger BioPharmaceuticals has had 1 split.
EIGR split history picture
Eiger BioPharmaceuticals (EIGR) has 1 split in our EIGR split history database. The split for EIGR took place on March 23, 2016. This was a 1 for 15 reverse split, meaning for each 15 shares of EIGR owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 66.6666666666667 share position following the split.

When a company such as Eiger BioPharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the EIGR split history from start to finish, an original position size of 1000 shares would have turned into 66.6666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Eiger BioPharmaceuticals shares, starting with a $10,000 purchase of EIGR, presented on a split-history-adjusted basis factoring in the complete EIGR split history. EIGR split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 01/31/2014
End date: 01/30/2023
Start price/share: $127.05
End price/share: $1.65
Dividends collected/share: $0.00
Total return: -98.70%
Average Annual Total Return: -38.28%
Starting investment: $10,000.00
Ending investment: $129.80
Years: 9.00
Date Ratio
03/23/20161 for 15
EIGR is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

EKSO Split History
ELGX Split History
ENSG Split History
ENZ Split History
EPRS Split History
ESMC Split History
ESRX Split History
ETRM Split History
EVFM Split History
EVHC Split History

Also explore: EIGR shares outstanding history

Email EnvelopeFree EIGR Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Liminal BioSciences Inc. (LMNL)
Galway Metals Inc. (GWM.CA)
Lannett Company, Inc. (LCI)
Reed's, Inc. (REED)
Phio Pharmaceuticals Corp. (PHIO)
Swvl Holdings Corp (SWVL)
Sientra, Inc. (SIEN)
Eargo, Inc. (EAR)
Alterity Therapeutics Limited (ATHE)
Aytu BioPharma, Inc. (AYTU)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

EIGR Insider Buying

EIGR Split History | www.SplitHistory.com | Copyright © 2013 - 2023, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.